Prolactin—A Biomarker for Antipsychotic Treatment Response?

Agarwal, Sri M. ; Rao, Naren P. ; Jhamnani, Kapil ; Venkatasubramanian, Ganesan ; Behere, Rishikesh V. ; Varambally, Shivarama ; Gangadhar, Bangalore N. (2011) Prolactin—A Biomarker for Antipsychotic Treatment Response? The Primary Care Companion For CNS Disorders, 13 (4). ISSN 2155-7780

Full text not available from this repository.

Official URL:

Related URL:


To the Editor: Antipsychotic-induced hyperprolactinemia, due to blockade of D2 receptors in the tubulo-infundibular dopaminergic pathway,1 has been examined predominantly from the perspectives of adverse effects.2 Interestingly, the “neuroleptic threshold” construct conceptualizes the D2/3 occupancy to underlie the clinical efficacy of antipsychotics.3 Antipsychotic-induced hyperprolactinemia, being a proxy indicator of D2 receptor occupancy of antipsychotics, is reported to be associated with clinical improvement in a short-term study.4 Intriguingly, prolactin has even been hypothesized to mediate the adaptive effects of antipsychotics.5 In this report, we describe association between hyperprolactinemia and clinical improvement during a 5-month treatment period.

Item Type:Article
Source:Copyright of this article belongs to PUBLONS.
ID Code:118827
Deposited On:30 May 2021 06:02
Last Modified:30 May 2021 06:02

Repository Staff Only: item control page